Vanguard Group’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $50.9M | Buy |
4,465,507
+50,385
| +1% | +$574K | ﹤0.01% | 2108 |
|
|
2025
Q1 | $52.5M | Buy |
4,415,122
+69,856
| +2% | +$830K | ﹤0.01% | 2081 |
|
|
2024
Q4 | $81.9M | Buy |
4,345,266
+333,452
| +8% | +$6.28M | ﹤0.01% | 1949 |
|
|
2024
Q3 | $90.1M | Buy |
4,011,814
+386,800
| +11% | +$8.69M | ﹤0.01% | 1921 |
|
|
2024
Q2 | $75.7M | Buy |
3,625,014
+1,040,714
| +40% | +$21.7M | ﹤0.01% | 1969 |
|
|
2024
Q1 | $38M | Sell |
2,584,300
-13,797
| -0.5% | -$203K | ﹤0.01% | 2284 |
|
|
2023
Q4 | $26.8M | Sell |
2,598,097
-116,748
| -4% | -$1.2M | ﹤0.01% | 2463 |
|
|
2023
Q3 | $21.3M | Buy |
2,714,845
+22,804
| +0.8% | +$179K | ﹤0.01% | 2522 |
|
|
2023
Q2 | $26.9M | Buy |
2,692,041
+68,586
| +3% | +$685K | ﹤0.01% | 2464 |
|
|
2023
Q1 | $23.3M | Buy |
2,623,455
+420,850
| +19% | +$3.74M | ﹤0.01% | 2530 |
|
|
2022
Q4 | $24.2M | Buy |
2,202,605
+41,739
| +2% | +$458K | ﹤0.01% | 2532 |
|
|
2022
Q3 | $28.2M | Buy |
2,160,866
+49,370
| +2% | +$643K | ﹤0.01% | 2476 |
|
|
2022
Q2 | $26.8M | Buy |
2,111,496
+83,433
| +4% | +$1.06M | ﹤0.01% | 2502 |
|
|
2022
Q1 | $28.4M | Buy |
2,028,063
+37,499
| +2% | +$525K | ﹤0.01% | 2587 |
|
|
2021
Q4 | $57.6M | Buy |
1,990,564
+12,613
| +0.6% | +$365K | ﹤0.01% | 2267 |
|
|
2021
Q3 | $59.3M | Buy |
1,977,951
+511,814
| +35% | +$15.3M | ﹤0.01% | 2270 |
|
|
2021
Q2 | $38.9M | Buy |
1,466,137
+303,153
| +26% | +$8.04M | ﹤0.01% | 2501 |
|
|
2021
Q1 | $36.2M | Buy |
1,162,984
+544,999
| +88% | +$16.9M | ﹤0.01% | 2482 |
|
|
2020
Q4 | $20.3M | Buy |
617,985
+81,865
| +15% | +$2.69M | ﹤0.01% | 2624 |
|
|
2020
Q3 | $18.7M | Buy |
+536,120
| New | +$18.7M | ﹤0.01% | 2489 |
|